Viruses 2010, 2(7), 1347-1366; doi:10.3390/v2071347

Resistance to Integrase Inhibitors

email, email, email and * email
Received: 27 April 2010; in revised form: 17 June 2010 / Accepted: 19 June 2010 / Published: 25 June 2010
(This article belongs to the Special Issue HIV Drug Resistance)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Integrase (IN) is a clinically validated target for the treatment of human immunodeficiency virus infections and raltegravir exhibits remarkable clinical activity. The next most advanced IN inhibitor is elvitegravir. However, mutant viruses lead to treatment failure and mutations within the IN coding sequence appear to confer cross-resistance. The characterization of those mutations is critical for the development of second generation IN inhibitors to overcome resistance. This review focuses on IN resistance based on structural and biochemical data, and on the role of the IN flexible loop i.e., between residues G140-G149 in drug action and resistance.
Keywords: AIDS; HIV-1 integrase; Raltegravir; Elvitegravir; GSK-1349572; GSK-1265744; interfacial inhibitors; resistance
PDF Full-text Download PDF Full-Text [1107 KB, Updated Version, uploaded 28 June 2010 15:47 CEST]
The original version is still available [583 KB, uploaded 25 June 2010 16:59 CEST]

Export to BibTeX |

MDPI and ACS Style

Métifiot, M.; Marchand, C.; Maddali, K.; Pommier, Y. Resistance to Integrase Inhibitors. Viruses 2010, 2, 1347-1366.

AMA Style

Métifiot M, Marchand C, Maddali K, Pommier Y. Resistance to Integrase Inhibitors. Viruses. 2010; 2(7):1347-1366.

Chicago/Turabian Style

Métifiot, Mathieu; Marchand, Christophe; Maddali, Kasthuraiah; Pommier, Yves. 2010. "Resistance to Integrase Inhibitors." Viruses 2, no. 7: 1347-1366.

Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert